The OncLive Brain Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of brain cancer, including glioma, glioblastoma multiforme, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.
May 26th 2022
Non-White Hispanic children and those with public insurance care in a clinical trial for high-risk neuroblastoma had inferior overall survival rates compared with other children.
May 19th 2022
Dabrafenib plus trametinib produced clinically meaningful objective responses rates in patients with recurrent or progressive BRAF V600E mutation–positive glioma.
April 1st 2022
A biologics license application seeking the approval of 131I-omburtamab in the treatment of pediatric patients with central nervous system/leptomeningeal metastases from neuroblastoma has been resubmitted to the FDA.
March 30th 2022
Encouraging response rates to a dual-targeted regimen in patients with recurrent or refractory malignant brain tumors with BRAF V600E mutations were reported in 2021, representing a new potential targeted therapy strategy against glioblastoma.
March 26th 2022
Navid Redjal, MD, FAANS, discusses technological advances that have impacted neurosurgical oncology.
March 11th 2022
Consortium seeks to advance underdeveloped area of brain cancer research, advance drug development, and improve treatment options for patients
March 9th 2022
A subset of patients with EGFR-positive glioblastoma experienced significantly longer progression-free survival when treated with adjuvant neratinib following chemoradiation vs adjuvant temozolomide alone, although no overall PFS benefit or any overall survival improvement was seen in the overall population.
January 11th 2022
The Data Safety Monitoring Board has determined that it is safe and appropriate to continue recruitment to the expansion arm of the phase 1/2 GLORIA trial, which is examining a novel combination comprised of NOX-A12, radiotherapy, and bevacizumab in glioblastoma and incomplete tumor resection.
January 11th 2022
Chemoimmunotherapy is still a relatively new strategy for patients with pediatric neuroblastoma, and the humanized anti-disialoganglioside monoclonal antibody hu14.18K322A could provide a breakthrough for children with high-risk disease.
December 6th 2021
The FDA has granted a fast track designation to ST101, a peptide antagonist of C/EBPβ, for the treatment of patients with recurrent glioblastoma.
November 8th 2021
A phase 0 trial that will evaluate niraparib in patients with newly diagnosed glioblastoma and recurrent glioma has just opened.
October 26th 2021
Concurrent use of tumor-treating fields, radiation therapy, and temozolomide is under study as a potential treatment for patients with newly diagnosed, stage IV glioblastoma.
October 25th 2021
Wenyin Shi, MD, PhD, discusses the rationale to evaluate a tumor-treating fields therapy in combination with temozolomide and radiation therapy in glioblastoma.
October 8th 2021
The FDA has granted a rare pediatric disease designation to lutetium-177-omburtamab-DTPA for use as a potential therapeutic option in pediatric patients with medulloblastoma, according to an announcement from Y-mAbs Therapeutics, Inc., the developer of the product.
August 30th 2021
The FDA has granted an orphan drug designation to LP-184 as a potential therapeutic option for patients with glioblastoma multiforme and other malignant gliomas.
August 25th 2021
The FDA has granted a fast track designation to the highly selective CK2 inhibitor silmitasertib as a potential therapeutic option for patients with recurrent sonic hedgehog–driven medulloblastoma
July 16th 2021
Cellular medicine could represent the next frontier in the treatment of patients with cancer and many other diseases with a high unmet need.
July 13th 2021
The FDA has granted a fast track designation to berubicin as a potential therapeutic option for patients with recurrent glioblastoma multiforme.
June 25th 2021
Amy B. Heimberger, MD, discusses the variability of responses in glioblastoma.